Association of microRNA-192, pentraxin-3, and transforming growth factor-beta1 with estimated glomerular filtration rate in adults with diabetic nephropathy
International Journal of Diabetes in Developing Countries - Trang 1-10 - 2023
Tóm tắt
Nephropathy is among the most pervasive complications of diabetes; it frequently results in end-stage renal disease and even death. However, current biomarkers for diabetic nephropathy (DN) have limited diagnostic utility. Thus, this present study aims to examine the associations of estimated glomerular filtration rate (eGFR) with plasma concentrations of microRNA-192 (miR-192), pentraxin-3 (PTX-3), and transforming growth factor-beta1 (TGF-β1) to identify biomarkers able to distinguish late-stage from early-stage DN. In total, 50 healthy volunteers and 271 diabetes patients were enrolled in this study. Participants were stratified into seven groups according to eGFR and glycated hemoglobin (HbA1c), healthy controls, diabetes without DN (G1), diabetes with mild renal impairment (G2), and 4 DN grades (G3a, G3b, G4, and G5). DN groups exhibited increases in serum miR-192 (p < 0.05), PTX-3(p < 0.05), TGF-β1(p < 0.05), malondialdehyde (p < 0.05), and xanthine oxidase (p < 0.05) levels and reductions in glutathione-s-transferase (p < 0.05) and superoxide dismutase (p < 0.05) compared to healthy controls. Among patients, eGFR was negatively correlated with miR-192, PTX-3, and TGF-β1, and positively correlated with HbA1c. In receiver operating characteristic curve analysis, miR-192 and PTX-3 demonstrated good diagnostic performance in distinguishing early from advanced DN. Elevated serum miR-192 and PTX-3 are associated with lower eGFR in DN, suggesting their utility as diagnostic and prognostic biomarkers.
Tài liệu tham khảo
Gheith O, Farouk N, Nampoory N, et al. Diabetic kidney disease: worldwide difference of prevalence and risk factors. J Nephropharmacol. 2016;5:49–56.
Lin YC, Chang YH, Yang SY, et al. Update of pathophysiology and management of diabetic kidney disease. J Formos Med Assoc. 2018;117(8):662–75. https://doi.org/10.1016/j.jfma.2018.02.007.
Fakhruddin S, Alanazi W, Jackson KE. Diabetes-induced reactive oxygen species: mechanism of their generation and role in renal injury. J Diabetes Res. 2017;8379327:1–30. https://doi.org/10.1155/2017/8379327.
Ma J, Wang Y, Xu HT, et al. MicroRNA: a novel biomarker and therapeutic target to combat autophagy in diabetic nephropathy. Eur Rev Med Pharmacol Sci. 2019;23:6257–63. https://doi.org/10.26355/eurrev_201907_18446.
Jin LW, Pan M, Ye HY, et al. Down-regulation of the long non-coding RNA XIST ameliorates podocyte apoptosis in membranous nephropathy via the miR-217-TLR4 pathway. Exp Physiol. 2019;104(2):220–30. https://doi.org/10.1113/EP087190.
Pathomthongtaweechai N, Hutipongtanate S. AGE/RAGE signaling-mediated endoplasmic reticulum stress and future prospects in non-coding RNA therapeutics for diabetic nephropathy. Biomed Pharmacother. 2020;131: 110655. https://doi.org/10.1016/j.biopha.2020.110655.
Dave VP, Ngo TA, Pernestig AK, et al. MicroRNA amplification and detection technologies: opportunities and challenges for point of care diagnostics. Lab Invest. 2019;99(4):452–69. https://doi.org/10.1038/s41374-018-0143-3.
Ma X, Lu C, Lv C, et al. The expression of miR-192 and its significance in diabetic nephropathy patients with different urine albumin creatinine ratio. J Diabetes Res. 2016;6789402. https://doi.org/10.1155/2016/6789402.
Sanjabi S, Oh SA, Li MO. Regulation of the immune response by TGF-β: from conception to autoimmunity and infection. Cold Spring Harb Perspect Biol. 2017;9(6): a022236. https://doi.org/10.1101/cshperspect.a022236.
Kim BG, Malek E, Choi SH, et al. Novel therapies emerging in oncology to target the TGF-β pathway. J Hematol Oncol. 2021;14:55. https://doi.org/10.10186/s13045-021-01053-x.
Zhang C, Ward J, Dauch JR, et al. Cytokine-mediated inflammation mediates painful neuropathy from metabolic syndrome. PLoS ONE. 2018;13(2): e0192333. https://doi.org/10.1371/journal.pone.0192333.
Chen C, Cui Q, Zhang X, et al. Long non-coding RNAs regulation in adipogenesis and lipid metabolism: emerging insights in obesity. Cell Signal. 2018;51:47–58. https://doi.org/10.1016/j.cellsing.2018.07.012.
Shindo A, Tanemura H, Yata K, et al. Inflammatory biomarkers in atherosclerosis: pentraxin 3 can become a novel marker of plaque vulnerability. PLoS ONE. 2014;9(6): e100045. https://doi.org/10.1371/journal.pone.0100045.
Zhou Y, Ni Z, Zhang J, et al. Plasma pentraxin 3 may be a better marker of peripheral artery disease in hemodialysis patients than C-reactive protein. Vasc Med. 2013;18:85–91. https://doi.org/10.1177/1358863X13483864.
Dawood AA, Kamel MA, Omar TA, Agaba AAM. Study of serum pentraxin 3 level in patients with diabetic nephropathy. Egypt J Intern Med. 2020;32:3. https://doi.org/10.4103/mmj.mmj_140_17.
Haneda M, Utsunomiya K, Koya D, et al. Joint Committee on Diabetic Nephropathy. A new Classification of Diabetic Nephropathy 2014: a report from Joint Committee on Diabetic Nephropathy. J Diabetes Investig. 2015;6(2):242–6. https://doi.org/10.1111/jdi.12319.
Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9. https://doi.org/10.1007/BF00280883.
Levey AS, Coresh J, Greene T, et al. Chronic Kidney Disease Epidemiology Collaboration. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standar-dized serum creatinine values. Clin Chem. 2007;53:766–72. https://doi.org/10.1373/clinchem.2006.077180.
Esterbauer H, Cheeseman KH. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol. 1990;186:407–21. https://doi.org/10.1016/0076-6879(90)86134-h.
Ozer N, Oglu MM, Ogus IH. A simple and sensitive method for the activity staining of xanthine oxidase. J Biochem Biopsy Methods. 1998;36:95–100. https://doi.org/10.1016/s0165-022x(97)00051-1.
Sinha AK. Colorimetric assay of catalase. Anal Biochem. 1972;47(2):389–94. https://doi.org/10.1016/0003-2697(72)90132-7.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 2001;25(4):402–8. https://doi.org/10.1006/meth.2001.1262.
Shu A, Du Q, Chen J, et al. Catalpol ameliorates endothelial dysfunction and inflammation in diabetic nephropathy via suppression of RAGE/RhoA/ROCK signaling pathway. Chem Biol Interact. 2021;348:109625. https://doi.org/10.1016/j.cbi.2021.109625.
Abdelaty TA, Morsy EY, El-Sayed ET, et al. Plasma microRNA-192 expression as a potential biomarker of diabetic kidney disease in patients with type 2 diabetes mellitus. Clin Diabetol. 2020;9(6):454–60. https://doi.org/10.5603/DK.2020.0045.
Abdel-Moneim A, Mahmoud B, Nabil A, Negeem Z. Correlation between oxidative stress and hematological profile abnormalities with diabetic nephropathy. Diabetes Metab Syndr. 2019;13:2365–73. https://doi.org/10.1016/j.dsx.2019.06.014.
Mahmoud B, Abdel-Moneim A, Negeem Z, Nabil A. The relationship between B-cell lymphoma 2, interleukin-1β, interleukin-17, and interleukin-33 and the development of diabetic nephropathy. Mol Biol Rep. 2021;49(5):3803–9. https://doi.org/10.1007/s11033-022-07221-7.
Huang Y, Chi J, Wei F et al (2020) Mitochondrial DNA: a new predictor of diabetic kidney disease. Int J Endocrinol ID 3650937. https://doi.org/10.1155/2020/3650937
Lodhi AH, Ahmad FD, Furwa K, Madni A. Role of oxidative stress and reduced endogenous hydrogen sulfide in diabetic nephropathy. Drug Des Devel Ther. 2021;15:1031–43. https://doi.org/10.2147/DDDT.S291591.
Itano S, Kadoya H, Satoh M, et al. Non-purine selective xanthine oxidase inhibitor ameliorates glomerular endothelial injury in InsAkita diabetic mice. Am J Physiol Renal Physiol. 2020;319:765–72. https://doi.org/10.1152/ajprenal.00236.2020.
Bessa SS, Ali EMM, El Gamal DM, et al. Erythrocyte GST activity in type 2 diabetes with and without nephropathy. DJS. 2020;42:100–7. https://doi.org/10.21608/DJS.2020.147773.
Abdel Hameed NA, Shaker OG, Hasona NA. Significance of LINC00641 and miR-378 as a potential biomarker for colorectal cancer. Comp Clin Pathol. 2022. https://doi.org/10.1007/s00580-022-03384-8.
Sun Y, Koo S, White N, et al. Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. Nucleic Acids Res. 2004;32(22): e188. https://doi.org/10.1093/nar/gnh186.
Saadi G, Meligi AE, El-Ansary M, et al. Evaluation of microRNA-192 in patients with diabetic nephropathy. Egypt J Intern Med. 2019;31(2):122. https://doi.org/10.4103/ejim.ejim_89_18.
Chien HY, Chen CY, Chiu YH, et al. Differential microRNA profiles predict diabetic nephropathy progression in Taiwan. Int J Med Sci. 2016;13(6):457–65. https://doi.org/10.7150/ijms.15548.
Li R, Chung AC, Yu X, Lan HY (2014) MicroRNAs in diabetic kidney disease. Int J Endocrinol 593956. https://doi.org/10.1155/2014/593956
Zhang Y, Jin D, Kang X, et al. Signaling pathways involved in diabetic renal fibrosis. Front Cell Dev Biol. 2021;9: 696542. https://doi.org/10.3389/fcell.2021.696542.
Kato M, Putta S, Wang M, et al. TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol. 2009;11(7):881–9. https://doi.org/10.1038/ncb1897.
Kato M, Wang L, Putta S, et al. Post-transcriptional up-regulation of Tsc-22 by Ybx1, a target of miR-216a, mediates TGF-{beta}-induced collagen expression in kidney cells. J Biol Chem. 2010;285(44):34004–15. https://doi.org/10.1074/jbc.M110.165027.
Bala C, Rusu A, Ciobanu DM, et al. The association study of high-sensitivity C-reactive protein, pentraxin 3, nitrotyrosine, and insulin dose in patients with insulin-treated type 2 diabetes mellitus. Ther Clin Risk Manag. 2018;28(14):955–63. https://doi.org/10.2147/TCRM.S162086.
Li B, Tian X, Guo S, et al. Pentraxin-3 and adropin as inflammatory markers of early renal damage in type 2 diabetes patients. Int Urol Nephrol. 2020;52:2145–52. https://doi.org/10.1007/s11255-020-02568-x.
Wang R, Zhang J, Hu W. Association of serum pentraxin 3 concentrations with diabetic nephropathy. J Investig Med. 2016;64:1124–7. https://doi.org/10.1136/jim-2016-000082.
Takashi Y, Koga M, Matsuzawa Y, et al. Circulating pentraxin-3 is positively associated with chronic hyperglycaemia but negatively associated with plasma aldosterone concentration. PLoS ONE. 2018;13(5): e0196526. https://doi.org/10.1371/journal.pone.0196526.
Tong M, Carrero JJ, Qureshi AR, et al. Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol. 2007;2:889–97. https://doi.org/10.2215/CJN.00870207.
Zhao L, Zou Y, Liu F. Transforming growth factor-Beta1 in diabetic kidney disease. Front Cell Dev Biol. 2020;8:187. https://doi.org/10.3389/fcell.2020.00187.
Mou X, Zhou DY, Zhou DY, et al. Serum TGF-β1 as a biomarker for type 2 diabetic nephropathy: a metaanalysis of randomized controlled trials. PLoS ONE. 2016;11(2): e0149513. https://doi.org/10.1371/journal.pone.0149513.
He X, Kuang G, Zuo Y, et al. The role of non-coding RNAs in diabetic nephropathy-related oxidative stress. Front Med. 2021;8: 626423. https://doi.org/10.3389/fmed.2021.626423.
Su H, Wan C, Song A, et al. Oxidative stress and renal fibrosis: mechanisms and therapies. Adv Exp Med Biol. 2019;1165:585–604. https://doi.org/10.1007/978-981-13-8871-2_29.
Qiao YC, Chen YL, Pan YH, et al. Changes of transforming growth factor beta 1 in patients with type 2 diabetes and diabetic nephropathy A PRISMA-compliant systematic review and meta-analysis. Medicine. 2017;96(15):e6583. https://doi.org/10.1097/MD.0000000000006583.
Shukla A, Kare K, Banerjee BD, et al. Study of serum transforming growth factor-beta 1 (TGF-β1) levels in type 2 diabetes mellitus patients with nephropathy. Biomed Res. 2018;29(16):3213–8. https://doi.org/10.4066/biomedicalresearch.29-18-950.
Shaker YM, Soliman HA, Ezzat E. Serum and urinary transforming growth factor beta 1 as a biochemical marker in diabetic nephropathy. BJBAS. 2014;3:16–23. https://doi.org/10.1016/j.bjbas.2014.02.002.
John P, Yadla M. Noninvasive method of differentiating diabetic nephropathy and nondiabetic renal disease using serum bone morphogenetic protein-7 and transforming growth factor-beta 1 levels in patients with type-2 diabetes mellitus. Saudi J Kidney Dis Transpl. 2019;30(6):1300. https://doi.org/10.4103/1319-2442.275474.